Skip to main content

Oncology vs. Neurology Licensing Deal Comparison

Oncology Median Upfront
$258M
Total: $1.6B
Neurology Median Upfront
$423M
Total: $3.7B
Oncology Royalty Range
11.8%-19.3%
Tiered to 23.3%
Neurology Royalty Range
13.1%-21%
Tiered to 25%
Model Your Deal

Market Analysis

Oncology and neurology represent the two highest-value therapeutic areas for pharmaceutical licensing, but with distinctly different deal economics. Phase 2 oncology small molecule deals carry a median total deal value of $1.6B versus $3.7B for neurology disease-modifying assets. Oncology upfronts average $258M compared to $423M for neurology.

The deal volume disparity is significant: oncology accounts for approximately 40% of all biopharma licensing deals, compared to 12-15% for neurology. However, neurology deal values have been trending upward with the clinical validation of disease-modifying approaches in Alzheimer's and Parkinson's. Development milestones are $345M for oncology versus $1.1B for neurology, reflecting the longer and more expensive clinical trial timelines in neurodegenerative disease.

Royalty structures differ by therapeutic area. Oncology base royalties range from 11.8% to 19.3%, while neurology deals support 13.1% to 21% base rates. Neurology deals often include indication expansion milestones that bridge into psychiatry and pain, adding option value not typically available in oncology deals.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

Do oncology deals command a premium over neurology deals?
Oncology deals generally carry higher total deal values ($1.6B vs $3.7B) at Phase 2, driven by higher deal volume, faster development timelines, and more validated regulatory endpoints. However, neurology disease-modifying assets with strong biomarker data can match or exceed oncology valuations on a per-indication basis.
How does deal volume compare between oncology and neurology?
Oncology accounts for roughly 40% of all biopharma licensing transactions, making it the most active therapeutic area by a wide margin. Neurology represents approximately 12-15% of deal volume but is the fastest-growing TA for licensing activity, driven by Alzheimer's disease-modifying therapies, Parkinson's gene therapies, and next-generation psychiatric medications.
How do royalty rate structures differ between oncology and neurology?
Oncology base royalties range from 11.8% to 19.3%, compared to 13.1% to 21% for neurology. Oncology benefits from higher pricing power and more concentrated patient populations, while neurology deals often incorporate broader indication expansion rights that effectively increase the total economic value to the licensor.

Related Benchmarks

Oncology Deal Overview 2026

View

Neurology & CNS Deal Overview

View

Phase 2 Deal Benchmarks

View

Small Molecule Deals

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating